 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).  Fármacos Para el Corazón - Página 78de Lionel H. Opie - 2005 - 456 páginasVista previa restringida - Acerca de este libro
 | Michel Safar, Michael F. O'Rourke - 2006 - 618 páginas
...until March 2003. / Hypertens 2003;21:1055-1076. ^. 67. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes...hypertensive patients randomized to angiotensin-converting o enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid- ^ Lowering... | |
 | Thomas Brandt - 2003 - 1606 páginas
...Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The Antihypertensive and Lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 283, 1967-1975. The Amaurosis Fugax Study Group (1990). Current management of amaurosis fugax. Stroke... | |
 | Scott Eric Kasner, Philip B. Gorelick - 2004 - 446 páginas
...trial against atenolol. Lancet 2002:359: 1004-1010. 49. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes...Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002:288:298 1-2997. 50. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme... | |
 | Sara T. Goulden - 2003 - 286 páginas
...randomized controlled trial. Journal of the American Medical Association, March 2001; 285:1482-1488. ALLHAT Collaborative Research Group. Major outcomes...Lipid-Lowering Treatment to Prevent Heart Attack Trial). Journal of the American Medical Association, December 2002; 288:2981-2997. Anderson J et al. Meta-analysis... | |
 | Steven P. Marso, David M. Stern (M.D.) - 2004 - 554 páginas
...pravastatin compared with other subgroups in this trial. III. DIABETES AND ANTIHYPERTENSIVE AGENTS Major Outcomes in High-Risk Hypertensive Patients...Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997. Clinical Relevance: This study compared the effects of an ACE inhibitor or calcium channel blocker... | |
 | Institute of Medicine, Food and Nutrition Board, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Panel on Dietary Reference Intakes for Electrolytes and Water - 2005 - 648 páginas
...Williamson J, Louis G, Ragusa P, Williard A, Ferguson RLS, Tanner J, Eckfeldt J, Crow R, Pelosi J. 2002. Major outcomes in high-risk hypertensive patients...Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 288:29812997. Gallen IW, Rosa RM, Esparaz DY, Young JB, Robertson GL, Batlle D, Epstein... | |
 | Steven P. Marso - 2003 - 107 páginas
...diabetes and systolic hypertension. N Engl J Med 1999;340:677-84. 48. The ALLHAT Officers. Major outeomes in high-risk hypertensive patients randomized to angiotensin-convertin...Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. 49. Krcisberg RA. Diabetic Dyslipidemia. Am J Cardiol 1998;82:67U-73U. 50. The Third... | |
 | Peter J. Sharis, Christopher P. Cannon - 2003 - 390 páginas
...(Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes...inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-2997 (editorials, 3039-3044). Design: Prospective, randomized, active-controlled,... | |
 | Thomas D. Koepsell, Noel S. Weiss - 2003 - 527 páginas
...Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967-75. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet... | |
| |
